ID: MRFR/HC/6984-HCR | February 2021 | Region: Global | 110 pages
Human Immunodeficiency Virus (HIV) Drugs Market size is expected to cross USD 33.7 Million by 2025 at a CAGR of 5% during the forecast period.
Human immunodeficiency virus (HIV) spreads through body fluids, such as blood and seminal fluid, and attacks the human immune system, especially CD4 cells (often called T cells). The weakening of the immune system results in the occurrence of opportunistic infections and results in acquired immunodeficiency syndrome (AIDS).
HIV infection cannot be cured completely. Hence, administering HIV drugs is necessary for controlling its spread and progression to AIDS.
Increasing awareness about HIV treatment, extensive research & development for new drugs, and a large number of patients diagnosed with HIV annually are impacting the market.
The number of individuals diagnosed with HIV has grown exponentially over the years. For instance, in 2018, the number of individuals infected by HIV worldwide was reportedly 1.7 million.
Due to the rising awareness of HIV infection and its treatment options, the number of individuals undergoing HIV treatment is increasing. For instance, in 2018, 23.3 million HIV patients were undergoing antiretroviral therapy (ART) globally. The number has increased by 1.6 million as compared to 2017 and 8 million as compared to 2010.
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): NRTIs are retroviral drugs that prevent HIV’s reverse transcriptase from appropriately copying its RNA into DNA. The segment growth is due to the launch of generic drugs. For instance, in March 2017, Lupin launched generic abacavir and lamivudine tablets in the American market.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Innovative product launch is driving the growth of this segment. For instance, Merck Co. & Inc., in November 2018, received approval for doravirine from the European Commission (EC) for the treatment of adults infected with HIV-1.
Protease Inhibitors (PIs): This class of drugs prevents HIV from maturing and infecting other healthy cells. Increased awareness regarding HIV treatment has resulted in an increase in demand for drugs. For instance, in 2018, Johnson & Johnson’s Prezista (darunavir) reported a 7.4% increase in its sales as compared to 2017.
Integrase Inhibitors: Drugs in this segment are under clinical trials. For instance, ViiV Healthcare, in April 2019, submitted a new drug application to the US Food and Drug Administration (FDA) for the two-drug regimen of cabotegravir and rilpivirine.
Fusion Inhibitors: Includes drugs that prevent the virus from entering healthy cells, thereby avoiding the onset of infection.
CCR5 Antagonist: This is a comparatively new class of antiretroviral drugs, prevent HIV from infecting CD4 T cells of the immune system. SELZENTRY (maraviroc) received approval from the US Food and Drug Administration (FDA) exclusively for the treatment of CCR5-tropic HIV-1 infection.
Post-Attachment Inhibitor or Monoclonal Antibody: The drugs in this category prevent the entry of the virus into the host cell. Currently, Trogarzo is the only approved drug in categorized in this segment.
Hospitals & Clinics: The largest segment, as hospitals and clinics are usually the primary places for the treatment of any disease.
Specialty Centers: Specialty centers are focused on providing treatment for a specific disease/ disorder. Increasing prevalence and awareness regarding HIV treatment is expected to drive the growth of this segment during the forecast period.
Americas: Holds the largest market share due to the presence of key market players and high healthcare expenditure.
Europe: The second-largest regional market due to factors such as product launches by key players.
Asia-Pacific: The fastest-growing regional market, due to increasing awareness regarding the use of HIV drugs and a significant section of the population affected by HIV.
Middle East & Africa: The smallest market due to limited healthcare infrastructure.
Frequently Asked Questions (FAQ) :
The valuation of the global human immunodeficiency Virus (HIV) drugs market is estimated to reach USD 33.7 MN by 2025.
The global human immunodeficiency Virus (HIV) drugs market is projected to grow at approximately 5% CAGR during the forecast period (2019-2025).
Presence of favorable reimbursement policies in developed countries.
North America holds the largest share in the global human immunodeficiency Virus (HIV) drugs market, followed by Europe and the Asia Pacific, respectively.
Cipla Inc. (India) Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Pfizer Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Aurobindo Pharma (India), ViiV Healthcare (UK), and Celltrion Healthcare Co., Ltd (South Korea), are some of the major players operating in the human immunodeficiency Virus (HIV) drugs market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.